18 results about "Adhesion protein" patented technology

The invention discloses a special membrane material for targeted trapping of macrobrachium larvae in water and a preparation method of the special membrane material, and belongs to the field of water environment biological pollution prevention and control. The membrane material is of a multi-layer composite structure and comprises a nanofiber membrane base material layer, an interface adhesion layer and a functional modification layer. The interface adhesion layer is bionic coacervate gel formed by curing hydrophobic polyelectrolyte and phytic acid; the functional modification layer is covalently grafted with a bionic adhesion protein active peptide fragment and a macrobrachium larva chemical pheromone. The material actively attracts larvae to approach through chemical pheromones, high-strength adhesion capture is achieved through bionic peptide fragments rich in aromatic and cationic amino acids, and trapping is integrated. The preparation method comprises the steps of electrostatic spinning of a base material, surface activation, gel coating, functional modification and the like. The material disclosed by the invention has high selectivity and high capture rate on the larvae of the Limnoperna fortunei, is environment-friendly, long-acting and stable, and is suitable for green prevention and treatment of fouling of the larvae of the Limnoperna fortunei in facilities such as water pipelines and pump stations.

This invention belongs to the biomedical field and relates to the application of a compound in preventing the recurrence of calcium oxalate kidney stones. The application of the compound, or its pharmaceutically acceptable salts, esters, solvates, crystal forms, or prodrugs, in the preparation of reagents for preventing the recurrence of calcium oxalate kidney stones is described. The structure of the compound is as follows: [structure details missing]. The calcium oxalate kidney stones originate from Randall plaques. Extensive experimental evidence demonstrates that Benathin can enhance intercellular adhesion by repairing the adhesion protein network damaged by hydroxyapatite (HAP), thereby reversing epithelial damage, preventing epithelial cell detachment, and effectively protecting the renal papillary mucosal barrier, thus reducing the risk of stone formation and recurrence of calcium oxalate kidney stones.

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

Provided is an immunogenic Mycoplasma pneumoniae polypeptide epitope, which is a polypeptide epitope derived from the key adhesion proteins P1, P30, P40 / 90 and P116 of type I and type II Mycoplasma pneumoniae, and / or the CARDS toxin thereof. Further provided is a recombinant protein, which contains one or more of the immunogenic Mycoplasma pneumoniae polypeptide epitopes. Further provided is a vaccine for preventing Mycoplasma pneumonia infections, which vaccine provides protection against at least one of type I and / or type II Mycoplasma pneumonia infections, and is characterized in that the vaccine contains the recombinant protein and is a vaccine capable of providing safe and effective protection against Mycoplasma pneumonia infections.

The present invention relates to a diagnostic composition comprising at least one peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (VDELERIRRSILPYGDSMDRIEKDR), SEQ ID NO: 2 (GGAGSLGAGGAFGEA), SEQ ID NO: 35 (GPAGPPGHPGPPGPR), SEQ ID NO: 4 (EGLITLTELADSLLS), SEQ ID NO: 5 (EFQYLTGGLIEPQVH), SEQ ID NO: 6 (SSHMLTDTKTGLHFN), SEQ ID NO: 7 (FIPGPPGPPGPPGPR), SEQ ID NO: 8 (INEAIEQGTIDKALV), SEQ ID NO: 9 (AFGEAAGDRGPYGTDI) and SEQ ID NO: 10 (LITLTELADSLLSRL). Furthermore, the present invention relates to an in vitro method for detecting the presence or absence of a disease selected from the group of bullous pemphigoid, Parkinson's disease, and a neurological disorder comprising testing the binding of at least one peptide as identified in any of the preceding claims for binding to autoantibodies obtained from a subject suspected of suffering from one of said diseases.

An antiviral coating composition is provided. An antiviral coating composition according to one embodiment of the present invention is implemented by including an antiviral component comprising an antiviral fusion protein in which an antiviral motif is bound to an adhesive protein. According to the present invention, the composition has excellent processability enabling easy provision on various surfaces of various products, has adhesion sustainability enabling an adhesive state to be maintained for a long period of time after being adhered to a surface, and has activity sustainability enabling antiviral activity to be maintained for a long period of time without a loss in activity according to external conditions during preparation, storage and use.

The application discloses a NEED short peptide modified polylactic acid implant material and a preparation method and application thereof, and relates to the technical field of biomedical materials. The preparation method of the NEED short peptide modified polylactic acid implant material provided by the application is as follows: an interface composed of polylactic acid material is constructed on the surface of an implant material substrate, the interface is activated, and the NEED short peptide is fixed on the interface. The polylactic acid implant material prepared by the application utilizes the interface composed of the polylactic acid material and the NEED short peptide with negative electricity to enhance the adhesion stability of adhesion proteins such as fibronectin and to enhance the subsequent cell adhesion response, thereby promoting cell adhesion and implant material integration. The material can be widely applied to the fields of degradable vascular stents, bone repair materials, dental implants, tissue engineering stents and nanofiber membranes, and can also provide a new technical scheme for interface functionalization of implant materials in a metabolic abnormal environment, and has a wide application prospect.

The present disclosure provides a pharmaceutical association comprising at least one growth factor receptor-binding compound, which activates at least one growth factor receptor of a neoplastic cell, and at least one adhesion protein inhibitor which inhibits at least one transmembrane cell adhesion protein of said neoplastic cell.

The application discloses a triplex forming oligonucleotide fluorescent probe and a detection method for detecting mycoplasma by targeting P1 adhesion protein genes, and belongs to the technical field of microbial molecular detection. The fluorescent probe is a triplex forming oligonucleotide (TFO), targets a specific conservative sequence of mycoplasma P1 adhesion protein genes, the 5' end of the fluorescent probe is modified with a fluorescent reporter group, the 3' end of the fluorescent probe is modified with a fluorescent quenching group, the fluorescent probe can form a stable triplex DNA complex with the target sequence through Hoogsteen base pairing and generate a fluorescent signal. The detection method comprises four core steps of sample pretreatment and DNA extraction, fluorescent probe incubation, fluorescent signal detection and result judgment, and does not need PCR amplification, and is simple in operation and rapid in detection. The probe has high specificity and high sensitivity, the detection lower limit can reach 1 copy / muL, is suitable for mycoplasma detection of various types of samples, and can be widely applied to scenes such as clinical diagnosis, biological pharmaceutical quality control and livestock breeding quarantine.

The invention belongs to the field of biomedicine, and relates to application of a compound in preventing relapse of calcium oxalate kidney stone. The invention relates to application of the compound or pharmaceutically acceptable salt, ester, solvate, crystal form or prodrug thereof in preparation of a reagent for preventing relapse of calcium oxalate kidney stone. The structure of the compound is shown in the specification; the calcium oxalate kidney stone is derived from a Randall plaque. A large number of experiments prove that Benarthin can repair an adhesion protein network damaged by hydroxyapatite HAP, so that intercellular adhesion is enhanced, epithelial injury is reversed, epithelial cells are prevented from falling off, and a renal papilla mucous membrane barrier is effectively protected, so that the risk of calculus formation and relapse of calcium oxalate kidney calculus is reduced.

The application belongs to the field of biotechnology, and particularly relates to a Mycoplasma bovum adhesion protein P24 and application thereof. A novel Mycoplasma bovum adhesion protein is identified by various biological and immunological methods, the protein can promote the combination of Mycoplasma bovum and host cells, and further research shows that the protein realizes the adhesion function by combining with heparin. In addition, the polyclonal antibody against the P24 protein can obviously inhibit the adhesion of Mycoplasma bovum to host cells, and the adhesion function is closely related to bacterial virulence. An effective target is provided for the development of novel vaccines, diagnostic and therapeutic preparations.

Provided is an adhesive protein that has high adhesive strength and low toxicity and can be efficiently produced. In addition, there is provided an adhesive protein having adhesiveness and additional functionality useful for medical and / or research applications. A recombinant protein includes a functional peptide portion having growth factor activity; and an adhesive peptide portion fused to an N-terminal side and an adhesive peptide portion fused to a C-terminal side of the functional peptide portion.

Disclosed in the present invention are a Pichia pastoris genetically engineered strain for the efficient surface display of an enzyme based on an adhesion protein, and a construction method therefor and the use thereof in immobilized continuous catalysis. An adhesion protein gene, a β-galactosidase gene LacA, and a cell wall anchoring protein gene Pir1p are expressed in the starting strain, Pichia pastoris. The Pichia pastoris genetically engineered strain is obtained by integrating and expressing a cell wall adhesion protein gene into the genome of Pichia pastoris GS115, integrating a β-galactosidase surface display gene in multiple copies, and displaying a target protein, β-galactosidase, on a yeast surface under the control of a constitutive promoter. The Pichia pastoris genetically engineered strain is capable of performing multi-batch continuous catalysis, and exhibits a catalytic effect superior to that of the enzyme surface display genetically engineered strain without an integrated biofilm gene.

The application belongs to the technical field of nucleic acid aptamer, and provides an application of an aptamer for visual detection of mycoplasma pneumoniae P1 adhesion protein. The aptamer for visual detection of mycoplasma pneumoniae P1 adhesion protein is labeled with a fluorescent marker on a base sequence shown in SEQ.ID.NO.1. The nucleic acid aptamer obtained by the application has high specificity and high affinity for mycoplasma pneumoniae P1 adhesion protein, the Kd value is 392.8 nM, the linear detection range is 480-1200 nM, and the detection limit is 145.50 nM. The application can be used for visual detection of mycoplasma pneumoniae P1 adhesion protein, and has a good application prospect.

The application discloses a kind of special membrane material for targeting trapping Corbicula fluminea larvae in water and a preparation method thereof, and belongs to the field of water environmental biological pollution prevention and control.The membrane material is a multilayer composite structure, including a nanofiber membrane substrate layer, an interface adhesion layer and a functional modification layer.The interface adhesion layer is a biomimetic condensed layer gel formed by hydrophobic polyelectrolyte and phytic acid solidification;The functional modification layer is covalently grafted with a biomimetic adhesion protein active peptide segment and a Corbicula fluminea larva chemical information substance.The material actively lures larvae by chemical information substance, and realizes high-strength adhesion capture by using a biomimetic peptide segment rich in aromatic and cationic amino acids, and is integrated with "trapping body".The preparation method includes the steps of electrospinning substrate, surface activation, coating gel and functional modification, etc.The material has high selectivity and high capture rate for Corbicula fluminea larvae, and is environmentally friendly, long-acting and stable, and is suitable for green prevention and control of Corbicula fluminea larvae pollution in facilities such as water conveying pipeline and pump station.

The application discloses a mytilus edulis byssal thread adhesion protein mutant and application thereof and a method for identifying mytilus edulis byssal thread phenotype characteristics, and relates to the technical field of biology. The amino acid sequence of the mytilus edulis byssal thread adhesion protein mutant is shown as SEQ ID NO. 4. The application discloses that a non-synonymous mutation in the coding region of the mytilus edulis Mfp3-6 gene can directly affect the functional characteristics of the protein, thereby establishing a clear cause-and-effect relationship between the genotype and the mytilus edulis byssal thread adhesion performance phenotype. The application further provides a mytilus edulis byssal thread adhesion protein mutant, which has excellent adhesion strength characteristics and shows a broad application prospect in the field of functional adhesion materials. The protein mutant can be widely applied to the development of medical glue, dressings and gel materials, and provides important technical support for the research and development of biomimetic adhesion technology and new biological materials, and has good industrialization potential and social value.

The present disclosure provides for a vaccine comprising an Acinetobacter adhesin protein or fragment thereof and a pharmaceutically acceptable carrier or adjuvant. The vaccine may be used for treating or preventing a urinary tract infection (UTI) in a subject in need thereof, particularly a catheter-associated UTI (CAUTI). In some embodiments, the Acinetobacter adhesin protein or fragment thereof is an isolated Acinetobacter chaperone-usher pathway (CUP) adhesin protein or immunogenic fragment thereof.

This invention relates to a gel or ointment comprising at least 2 to 4 wt% of a thickener (optionally agar), at least 50 to 95 wt% of glycerol, and at least 0.03 to 3 wt% of an epithelial adhesion protein complex. The gel or ointment of this invention is formulated to deliver and maintain local and perceptible effects through the activity of the protein complex in the oral mucosa, thereby repairing and maintaining oral health in mammals or animals (such as canines).